New promises for metformin: advances in the understanding of its mechanisms of action

被引：17

作者：

Foretz, Marc ^{[1
,2
,3
]}

Viollet, Benoit ^{[1
,2
,3
]}

机构：

[1] INSERM, Inst Cochin, U1016, Dept Endocrinol Metab & Diabet, F-75014 Paris, France

[2] CNRS, UMR8104, Paris, France

[3] Univ Paris 05, Sorbonne Paris Cite, Paris, France

来源：

M S-MEDECINE SCIENCES | 2014年 / 30卷 / 01期

关键词：

ACTIVATED PROTEIN-KINASE; C; ELEGANS; INHIBITION; PATHWAY; CANCER; LKB1; AMPK; GLUCONEOGENESIS; METABOLISM; RESPONSES;

D O I：

10.1051/medsci/20143001018

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Metformin is currently the drug of first choice for the treatment of type 2 diabetes. However, although prescribed since the end of the 1950s, the mechanism of action of metformin remains as yet incompletely understood but recent work has unveiled novel and surprising properties. Epidemiological reports have suggested that metformin protects against heart failure and has antitumor properties independent of its anti-hyperglycemic effect. Here, we review the proposed mechanisms for metformin action in diabetes, cardiovacular diseases and cancer.

引用

页码：82 / 92

页数：11

共 53 条

[1]

Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage [J].

Algire, Carolyn ;

Moiseeva, Olga ;

Deschenes-Simard, Xavier ;

Amrein, Lilian ;

Petruccelli, Luca ;

Birman, Elena ;

Viollet, Benoit ;

Ferbeyre, Gerardo ;

Pollak, Michael N. .

CANCER PREVENTION RESEARCH, 2012, 5 (04) :536-543

[2]

If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice [J].

Anisimov, Vladimir N. ;

Berstein, Lev M. ;

Popovich, Irina G. ;

Zabezhinski, Mark A. ;

Egormin, Peter A. ;

Piskunova, Tatiana S. ;

Semenchenko, Anna V. ;

Tyndyk, Margarita L. ;

Yurova, Maria N. ;

Kovalenko, Irina G. ;

Poroshina, Tatiana E. .

AGING-US, 2011, 3 (02) :148-157

[3]

[Anonymous], MED MAL METAB

[4]

[Anonymous], MED MAL METAB

[5]

[Anonymous], MAROC MED

[6]

METFORMIN DECREASES GLUCONEOGENESIS BY ENHANCING THE PYRUVATE-KINASE FLUX IN ISOLATED RAT HEPATOCYTES [J].

ARGAUD, D ;

ROTH, H ;

WIERNSPERGER, N ;

LEVERVE, XM .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 213 (03) :1341-1348

[7]

Bailey C.J., 2007, Metformin-The Gold Standard: A Scientific Handbook

[8]

Which anti-tumour benefits to be expected from metformin? [J].

Beck, Emmanuel ;

Scheen, Andre J. .

ANNALES D ENDOCRINOLOGIE, 2013, 74 (02) :137-147

[9]

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level [J].

Ben Sahra, I. ;

Laurent, K. ;

Loubat, A. ;

Giorgetti-Peraldi, S. ;

Colosetti, P. ;

Auberger, P. ;

Tanti, J. F. ;

Le Marchand-Brustel, Y. ;

Bost, F. .

ONCOGENE, 2008, 27 (25) :3576-3586

[10]

Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1 [J].

Ben Sahra, Isaam ;

Regazzetti, Claire ;

Robert, Guillaume ;

Laurent, Kathiane ;

Le Marchand-Brustel, Yannick ;

Auberger, Patrick ;

Tanti, Jean-Francois ;

Giorgetti-Peraldi, Sophie ;

Bost, Frederic .

CANCER RESEARCH, 2011, 71 (13) :4366-4372

← 1 2 3 4 5 6 →